| Literature DB >> 16877817 |
Jian-Min Chen1, Claude Férec, David N Cooper.
Abstract
LINE-1 (L1) elements are the most abundant autonomous non-LTR retrotransposons in the human genome. Having recently performed a meta-analysis of L1 endonuclease-mediated retrotranspositional events causing human genetic disease, we have extended this study by focusing on two key issues, namely, mutation detection bias and the multiplicity of mechanisms of target gene disruption. Our analysis suggests that whereas an ascertainment bias may have generally militated against the detection of autosomal L1-mediated insertions, autosomal L1 direct insertions could have been disproportionately overlooked owing to their unusually large size. Our analysis has also indicated that the mechanisms underlying the functional disruption of target genes by L1-mediated retrotranspositional events are likely to be dependent on several different factors such as the type of insertion (L1 direct, L1 trans-driven Alu, or SVA), the precise locations of the inserted sequences within the target gene regions, the length of the inserted sequences, and possibly also their orientation.Entities:
Year: 2006 PMID: 16877817 PMCID: PMC1510945 DOI: 10.1155/JBB/2006/56182
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
L1 endonuclease-mediated retrotranspositional events known to cause human genetic disease. *
| Disrupted gene | Chrom. location | Inserted element | Insertion size (bp)/orientation | Length of | Location of insert | Target gene disruption | Original detection method | Reference |
| poly (A) | within the target | |||||||
| tail (bp) | gene | |||||||
| 5q | L1 Ta | 520/S | 222 | E15 | — | Southern blotting | [ | |
| Xq | L1 Ta | 6017/AS | 71 | E6 (+35; −82) | Skipping of E6 | Initially failed to | [ | |
| amplify exon 6 | ||||||||
| Xp | L1 Ta | 836/S | 69 | I5 (+1864; −278) | Complex splicing | RT-PCR | [ | |
| Xp | L1 Ta | 1722/S | 101 | E4 | — | Southern blotting | [ | |
| Xp | L1 Ta | 1400/S | 38 | E48 | — | Southern blotting | [ | |
| Xp | L1 Ta | 530/AS | 73 | 5'-UTR (see text) | No expression of | RT-PCR | [ | |
| muscle form | ||||||||
| transcript | ||||||||
| Xq | L1 Ta | 3800/S | 54 | E14 | — | Southern blotting | [ | |
| Xq | L1 preTa | 2300/AS | 77 | E14 | — | Southern blotting | [ | |
| Xq | L1 Ta | 463/S | 68 | E5 | — | Not specified | [ | |
| Xq | L1 Ta | 163/S | 125 | E7 | — | PCR | [ | |
| 11p | L1 Ta | 6000/AS | 107 | I2 (+765; −85) | Reduced mRNA | Southern blotting | [ | |
| expression (15%) | ||||||||
| Xp | L1 Ta | 6000/S | 64 | I1 (+633; −15641) | No mRNA | Southern blotting | [ | |
| expression | ||||||||
| Xp | L1 HS | 2800/AS | Yes | I3 (+5177; −8) | Skipping of E4 | Initially failed to | [ | |
| amplify exon 4 | ||||||||
| 5q | 278/S | 40 | E15 | — | PCR | [ | ||
| 3q | 289/S | 38 | E2 | — | Southern blotting | [ | ||
| 17q | 286/S | Yes | E11 | — | Protein truncation test | [ | ||
| 13q | 281/S | 62 | E22 (+36; −163) | Skipping of E22 | PCR | [ | ||
| 13q | 285/S | Yes | E3 | Skipping of E3 | Southern blotting | [ | ||
| Xq | —/AS | — | E8 | — | PCR | [ | ||
| Xq | 281/S | 74 | E9 | — | PCR | [ | ||
| 3q | 280/AS | 93 | E7 | — | PCR | [ | ||
| Xp | 281/S | 50 | E11 | Skipping of E11 | PCR | [ | ||
| 1q | —/AS | 70 | E7 | — | PCR | [ | ||
| 8q | —/AS | 97; 31 | E10 | — | Southern blotting | [ | ||
| Xq | 288/AS | 37 | I18 (+1734; −5) | Skipping of E19 | PCR | [ | ||
| Xq | 244/S | 78 | E5 | — | Southern blotting | [ | ||
| Xq | 237/S | 39 | E5 | — | PCR | [ | ||
| Xq | 279/AS | 40 | E8 | — | Not specified | [ | ||
| 10q | 283/AS | 69 | I8 (−2) | Skipping of E9 | PCR | [ | ||
| 10q | 288/AS | 47 | E9 | — | PCR | [ | ||
| Xp | 241/AS | 74 | I4 (+13629; −42) | See text | PCR | [ | ||
| 3p | 288/S | 30 | E3 | Complex splicing | PCR | [ | ||
| 11q | 279/AS | 39 | E5 (+32; −18) | No mRNA | PCR | [ | ||
| expression | ||||||||
| Xq | —/AS | — | I7 (−17) | — | PCR | [ | ||
| 17q | 282/AS | 40 | I40 (+134; −27) | Skipping of E41 | Southern blotting | [ | ||
| 11q | 285/S | 42 | I6 | — | Not specified | [ | ||
| 10q | 281/AS | 33 | I7 (+1212; −50) | Skipping of E8 | RT-PCR | [ | ||
| 2q | 281/S | 93 | E8 | — | PCR | [ | ||
| 1p | SVA | 2600/S | 57 | I1 (+687; −9453) | No expression | Initially failed to | [ | |
| amplify a small | ||||||||
| region of intron 1 | ||||||||
| in a homozygous | ||||||||
| patient | ||||||||
| Xq | SVA | 491/S | 74 | E9 (+51; −26) | Skipping of E9 | Initially failed to | [ | |
| amplify E9 by PCR | ||||||||
| 9q | SVA | 3062/S | Yes | 3'-UTR (see text) | Nearly no | Southern blotting | [ | |
| expression | ||||||||
| 1q | SVA | 632/S | 50 | E5 (+60; −87) | Skipping of E5 | RT-PCR | [ | |
| Xp | L1 Ta | 608/AS (Δ1 bp) | 16 | E44 (+145; −3) | Skipping of E44 | PCR | [ | |
| 9q | L1 Ta | 1200/S (Δ6 bp) | 59 | I7 (+2527; −24) | Complex splicing | Southern blotting | [ | |
| Xq | 98/S (Δ4726 bp) | 20 | I5 | NA | Initially failed to | [ | ||
| amplify several | ||||||||
| exons by PCR | ||||||||
| 5q | 93/AS (Δ1599 bp) | 60 | E14 | NA | In vitro synthesized- | [ | ||
| protein assay | ||||||||
| Xq | 290/AS (Δ2 bp) | 47 | E14 | — | Southern blotting | [ | ||
| 1q | 6/AS (Δ1444 bp) | 40 | I3b | NA | Southern blotting | [ | ||
| 4q | NA | NA/AS (Δ2076 bp) | 37 | I8 | NA | RT-PCR | [ | |
| 13q | NA | NA/S (Δ6212 bp) | 35 | I13 | NA | Southern blotting | [ | |
| Xq | NA | NA/AS (Δ > 40 kb) | 70 | I2 | NA | Southern blotting | [ | |
*The entries are presented in the same order as in Table 2 from Chen et al [6] for easy comparison, except for the addition of three simple Alu insertions (BRCA1 [21]; BRCA2 [21]; and HESX1 [27]) that have been reported during the preparation of this review. Data on chromosomal location, inserted element and orientation, insertion size, and length of poly (A) tail were derived from Table 2 in Chen et al [6].
aWith respect to the sense strand of the disrupted gene. S, sense; AS, antisense. The lengths of the genomic deletions associated with L1-mediated retrotransposons and simple poly (A) insertions are indicated in parentheses.
bI, intron; E, exon. When an insertion occurred into an intron/exon and accompanying RNA analysis data were available, the position of the insertion's integration site was indicated in parentheses (+, relative to the first nucleotide of the intron/exon; −, relative to the last nucleotide of the intron/exon).
cOnly the effect on the target gene's pre-mRNA splicing and/or mRNA expression was evaluated.
dThe method that initially suggested/identified the mutation at the nucleotide level. PCR indicates all PCR-based techniques using genomic DNA as templates.
eData not available.
fPoly (A) tail present but number of residues not specified.
g97 bp in the affected mother and 31 bp in the affected daughter, respectively.
hNot applicable.
X-chromosome/autosome comparison with respect to gene number, disease genes, known mutations, and retrotranspositional insertion events.
| No. of | No. of L1 direct | Known/putative | Diseases/traits in OMIM | Disease genes in HGMD | Mutations in HGMD | ||
| insertions causing | insertions causing | Size (Mb) | genes in the | ||||
| genetic disease | genetic disease | human genome | |||||
| A: X chromosome | 11 | 12 | 155 | 1,098 | 895 | 124 | 10010 |
| B: autosomes+ Y | 18 | 3 | 3045 | ∼ 39,000 | 14,977 | 1877 | 42155 |
| (A/B) % | 65.1 | 400 | 5.1 | 2.8 | 6.0 | 6.6 | 23.8 |
a, bData from [20].
cData from OMIM (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM&itool=toolbar) as of April 2005.
d, eData from HGMD (http://www.hgmd.org/) as of April 2005.